Garasone · DIN 00682217 · 3 mg & 1 mg/mL · Oph/Ot Drops
General benefit; Health Canada lists this DIN as Cancelled post market since 2014-04-01 — choose a marketed DIN from the same-category list.Discontinued April 1, 2014 · checked November 18, 2026
StatusGeneral benefit; Health Canada lists this DIN as Cancelled post market since 2014-04-01 — choose a marketed DIN from the same-category list.
Write on scriptno code needed; Health Canada lists this DIN as Cancelled post market since 2014-04-01 — choose a marketed DIN from the same-category list.
Patient paysODB senior: $100/program-year deductible
• Then up to $6.11 per prescription
Or, if enrolled in the Seniors Co-Payment Program (income-tested; individual net income below $25,480 for Aug 2026–Jul 2027): no deductible, up to $2 per prescription
Private plan not entered. Private-plan coverage, and how it coordinates with public programs, is not determined here; the Ontario public-program lines on this page remain conditional on the entered details and the program rules.
No interchangeable product listed in the Ontario extract
Garasone · DIN 00682217
Manufacturer: Schering Canada Inc.; listing date 1996-10-01
Health Canada: Cancelled post market since 2014-04-01 · brand GARASONE OPHTHALMIC AND OTIC SOLUTION · ATC S03CA06 BETAMETHASONE AND ANTIINFECTIVES · form Solution · route Ophthalmic, Otic · ingredients BETAMETHASONE (BETAMETHASONE SODIUM PHOSPHATE) 1 MG/ML, GENTAMICIN (GENTAMICIN SULFATE) 3 MG/ML · company Merck canada inc · schedule Prescription
Garasone: Formulary list price $1.28 per unit (the source does not state the unit; exact figure $1.2813). What the ministry pays, not the patient.
Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 00682217)
Source record
DIN 00682217: Garasone
Raw flags: sec3=Y
Item: 520404025; group id 579; item number 1534; lccId None; manufacturer id SCH
Source form: Oph/Ot Drops; strength: 3mg & 1mg/mL
Recorded listing: General benefit
Source prices (unrounded): $1.2813; ministry $1.2813
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=00682217
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=7418
Therapeutic Notes (formulary)
The risk of ototoxicity with topical aminoglycoside may increase with prolonged therapy. Topical use of antibiotics increases the likelihood of development of bacterial resistance, especially with prolonged use, sometimes rendering the systemic use of this antibiotic class useless in these patients.
Shortage status: not checked (no credentials)
Health Canada lists this DIN as Cancelled post market since April 1, 2014 — choose a marketed DIN from the same-category list.